|
Match
|
Document |
Document Title |
|
|
US20090275611 |
Compounds Which Modulate The CB2 Receptor
Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R 1 , R 2 , R 3 , X and Ar have the...
|
|
|
US20090263471 |
Controlled Release Pharmaceutical Composition of Venlafaxine Hydrochloride, and Process for Preparation Thereof
Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly...
|
|
|
US20090258948 |
PHARMACEUTICAL SALTS
The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these...
|
|
|
US20090258067 |
MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition...
|
|
|
US20090258064 |
COMPOSITIONS OF UCP INHIBITORS, FAS ANTIBODY, A FATTY ACID METABOLISM INHIBITOR AND/OR A GLUCOSE METABOLISM INHIBITOR
Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a...
|
|
|
US20090253761 |
BENZOCYCLOHEPTYL ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR ACTIVITY
Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at...
|
|
|
US20090246145 |
Imaging Correlates of Neurogenesis With MRI
This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises...
|
|
|
US20090234020 |
Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities
The present invention provides isolated O-desmethylvenlafaxine impurities ODV-Dimer and ODV-N-Dimer, their use as a reference marker and reference standard, and a process for the preparation of...
|
|
|
US20090232886 |
ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING
Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation...
|
|
|
US20090226500 |
SUTURES AND ANTI-SCARRING AGENTS
Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described...
|
|
|
US20090215905 |
Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
This invention relates to novel substituted aryloxy alkylamines useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a...
|
|
|
US20090209461 |
MODIFICATION OF FEEDING BEHAVIOR
Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist...
|
|
|
US20090203797 |
Antimycotic Patch
A nail and/or skin patch for preventing or treating mycoses is provided that is able to maintain a drug concentration in the nails and/or skin horny layer at a high concentration for a long period...
|
|
|
US20090203764 |
INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES
Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of...
|
|
|
US20090203607 |
Method And Compositions For Simultaneously Regulating Memory And Mood
The present invention is concerned with methods and compositions for simultaneously treating or modulating memory and mood within the same individual.
|
|
|
US20090197968 |
Extended-release capsules comprising venlafaxine hydrochloride
A capsule comprising venlafaxine hydrochloride wherein part of the drug content is in the form of delayed-release coated spheroids and a second part of the drug content is in a prompt-release form.
|
|
|
US20090192128 |
GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the...
|
|
|
US20090192125 |
Local anti-infective agent for treatment of nail fungal infections
A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or...
|
|
|
US20090176878 |
GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE
The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene....
|
|
|
US20090176698 |
Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
The invention relates to compositions comprising benzimidazolone derivatives of formula (I), optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts...
|
|
|
US20090175945 |
Systems, Methods, and Formulations for Topically Treating Nail Fungal Infections and Nail Psoriasis
The present invention is drawn to systems, methods, and formulations for treating nail disorders. The system comprises an active agent formulation and a first barrier film. The active agent...
|
|
|
US20090156672 |
Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include...
|
|
|
US20090148541 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEBORRHEA
Methods and compositions are provided for treating dermatological diseases, disorders, and pathologies, including seborrheic dermatitis, in a subject in need thereof. In some embodiments, methods...
|
|
|
US20090143479 |
PHARMACEUTICAL COMPOSITIONS COMPRISING TERBINAFINE
This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration.
|
|
|
US20090137685 |
Therapeutic Agent for Inflammatory Bowel Disease Containing as Active Ingredient 2-Amino-1,3-Propanediol Derivative, or Method for Treating Inflammatory Bowel Disease
A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases. The agent comprises a 2-amino-1,3-propanediol derivative (e.g.,...
|
|
|
US20090099202 |
External Preparation for Athlete's Foot Treatment
External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at...
|
|
|
US20090099154 |
Pharmaceutical Sustained Release Compositions and Processes Thereof
Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral...
|
|
|
US20090093513 |
Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: ...
|
|
|
US20090088434 |
Antifungal Composition
The invention provides a topical liquid antifungal composition containing an antifungal agent, a film-forming agent and a solvent. The composition is applied on the infected skin area to form a...
|
|
|
US20090076162 |
DEUTERIUM-ENRICHED DESVENLAFAXINE
The present application describes deuterium-enriched desvenlafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090076161 |
DEUTERIUM-ENRICHED BUPROPION
The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090053310 |
NOVEL SUSTAINED RELEASE DOSAGE FORM
The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer...
|
|
|
US20090041667 |
Treatment of Depressive Disorders
The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and...
|
|
|
US20090029922 |
Use of S1P receptor agonists in heart diseases
The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
|
|
|
US20090017102 |
Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion
The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a...
|
|
|
US20090012180 |
Titration of Tapentadol
The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of...
|
|
|
US20090012161 |
Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
This invention describes a new combination for the treatment of bladder function disorders which comprises a serotonin- and/or norepinephrine-reuptake inhibitor and a beta-3-adrenoceptor agonist.
|
|
|
US20090005455 |
N-OXIDES OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AS PRODRUGS
Embodiments of the invention relate to a compound of formula (1),
or a tautomer, stereoisomer, hydrate, or solvate thereof, wherein R 1 is H or CH 3 . Other embodiments of the invention relate...
|
|
|
US20080317737 |
Drug combination for the treatment of skin disorders
A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent formulated into shampoos, creams, lotions, gels,...
|
|
|
US20080312163 |
Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating...
|
|
|
US20080306161 |
Use of Axomadol for Treatment of Arthrosis Pain
The use of axomadol for the treatment of pain in arthrosis.
|
|
|
US20080299220 |
HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES
A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said...
|
|
|
US20080299197 |
Triple Combination Release Multi-Layered Tablet
This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( 1...
|
|
|
US20080299060 |
Pharmaceutical Composition for the Treatment of Nail Diseases
A method for topically and systemically delivering a pharmaceutical composition to a human nail is disclosed, said method comprising the application of a pharmaceutical composition to the nail,...
|
|
|
US20080293808 |
Non-Steroidal Androgen Receptor Modulators, Preparation Process, Pharmaceutical Composition and Use Thereof
Non-steroidal androgen receptor modulating compounds of the general formula (I), their pharmaceutically acceptable salts, preparation process and pharmaceutically compositions containing the said...
|
|
|
US20080293735 |
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of...
|
|
|
US20080286356 |
Pharmaceutical compositions containing terbinafin and use thereof
Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated...
|
|
|
US20080275131 |
COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE
This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use.
|
|
|
US20080262411 |
DYNAMIC NERVE STIMULATION IN COMBINATION WITH OTHER EATING DISORDER TREATMENT MODALITIES
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve...
|
|
|
US20080255181 |
Methods for treating podocyte-related disorders
The present invention relates to methods for treating or preventing podocyte-related diseases and disorders using compounds that modulate the calcium sensing receptor or pharmaceutical compositions...
|